What this study is
The study will examine how the performance of Oscillating Lung Expansion (OLE) therapy affects the respiratory health of patients with Bronchiectasis (BE).
The patient will use the BiWaze Clear system for their airway clearance therapy, instead of their previously prescribed therapy. BiWaze Clear is an FDA-cleared respiratory therapy for assisting patients in loosening and mobilizing secretions as well as treating and preventing atelectasis by providing lung expansion and high-frequency oscillation therapies, combined with aerosol delivery.
The patient will perform airway clearance with BiWaze Clear as prescribed. The system uses a disposable breathing circuit, which is a single patient use, disposable circuit.
The treatment duration is 6 months . The BiWaze Clear System is indicated for the mobilization of secretions, lung expansion therapy, the treatment and prevention of pulmonary atelectasis and has the ability to provide supplemental oxygen when used with an oxygen supply.
What's being tested
- BiWaze Clear System
Intervention · DEVICE
The BiWaze Clear device includes several components as follows: 1. BiWaze Clear System. 2. BiWaze Clear Dual Lumen Breathing Circuit. * Dual Lumen bacterial/viral filter. * Dual Lumen breathing tube. * Patient Interface (Anesthesia mask [small, medium or large], Mouthpiece, or trach adapter). 3. Carrying Bag. The patient will perform airway clearance therapy with the BiWaze Clear System
Study details
- Official title
- Oscillating Lung Expansion (OLE) Therapy in the Bronchiectasis Patients (BE) Home Care Study Protocol
- Sponsor
- Delve Health
- Conditions
- Bronchiectasis · Pulmonary Exacerbation
- Enrolling
- 85 people
- Starts
- 2025-05-20
- Est. completion
- 2026-08-31
- Design
- Open-label, single group
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 5 Years – 85 YearsSex ALLHealthy volunteers Not acceptedYou may qualify if
- Patients aged 5 to 85 years old.
- History of one or more respiratory exacerbations in the past 6 months or two or more respiratory exacerbations in the past 12 months, which required unplanned or unscheduled medical intervention.
- Ability to perform BiWaze Clear therapy as prescribed.
- Bronchiectasis diagnosis (including patients with cystic fibrosis with documented bronchiectasis).
- Signed informed consent (and Child assent if minor subject).
You can't join if
- Diagnosis with rapidly progressing NMD.
- Post bronchodilator FEV₁ ≥ 65 % predicted
- Anticipated requirement for hospitalization within the next six months.
- History of pneumothorax within the past 6 months.
- Use of OLE therapy within the past 12 months.
- Inability or unwillingness to perform OLE therapy or study procedures as required.
- Currently enrolled in a different study.
- Current smoker or tobacco use within the last 30 days.
- Pregnancy or Breastfeeding.
- Any medical conditions deemed by investigators to have a significant impact on the study results, e.g., active cancer, severe cardiovascular, severe progressive pulmonary disease, liver, kidney, or neurological conditions.
- Inability to comply with the treatment protocol or study procedures.
- Known allergies to materials used in OLE device.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (4)
4 openCentral Florida Pulmonary Group, P.A.
Orlando, Florida, United States
- Daniel T. Layish, MD,FACP,FCCP,FAASM · Contact407-841-1100dlayish@cfpulmonary.com
- Wilma Uy, RN, CRC · Contact(407) 841-1100 ext. 121wuy@cfpulmonary.com
RecruitingTreasure Coast Medical Research Group, LLC
Port Saint Lucie, Florida, United States
- Mark Pamer, MD · Contact7727855864mpamer@markjpamerdo.com
- Nicole Trujillo, CRC · Contact7727855864 ext. 5ntrujillo@tcmrg.com
RecruitingMetropolitan Clinical Research
Tamarac, Florida, United States
- Hector Vazquez, MD · Contact(954) 569 - 6820hector.vazquez@metropolitancrc.com
- Osmani Placencia, MD · Contact(954) 569 - 6820. ext. 202osmani.placencia@metropolitancrc.com
RecruitingUniversity of South Florida -Tampa General Hospital
Tampa, Florida, United States
- Chak Sriaroon, MD · Contact813 810 5700csriaroo@usf.edu
- Gabriel Parker, PM · Contact813 810 5700gparker4@usf.edu
Not yet recruiting
Study team
Sponsor
Delve Health
Study ID BiWaze Clear_001
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.